Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid function tests

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: Thyroid function tests. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-004451-35 Sponsor Protocol Number: MRTSH01505 Start Date*: 2007-03-13
    Sponsor Name:Genzyme Europe BV
    Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi...
    Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043808 Thyrotropin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001978-28 Sponsor Protocol Number: J2G-MC-JZJB Start Date*: 2020-01-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-M...
    Medical condition: Male or female patients with progressive, advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2011-000719-19 Sponsor Protocol Number: 09/100/10 Start Date*: 2011-05-05
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies. (TABLET: Thyroid AntiBodies and LEvoThyro...
    Medical condition: Thyroid autoimmunity and history of miscarriage or infertility.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000212-28 Sponsor Protocol Number: LOXO-RET-18036 Start Date*: 2020-04-15
    Sponsor Name:Loxo Oncology, Inc.
    Full Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
    Medical condition: Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007959 Central nervous system neoplasm NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049516 Malignant tumor LLT
    20.1 100000004852 10007960 Central nervous system neoplasms malignant NEC HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023509-37 Sponsor Protocol Number: IIT2010 Start Date*: 2011-06-29
    Sponsor Name:Institut für klinische Forschung und Entwicklung Berlin GmbH am St. Hedwig Krankenhaus
    Full Title: A prospective, randomized, single-blind, placebo-controlled, two-armed, phase IV study in patients with subclinical hypothyroidism treated over 52 weeks either with levothyroxine in adjusted dosing...
    Medical condition: Subclinical hypothyroidism
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002699-98 Sponsor Protocol Number: CB001-OL Start Date*: 2015-04-14
    Sponsor Name:University of Oxford
    Full Title: OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability
    Medical condition: Bipolar disorder with current mood instability
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10004908 Bipolar affective disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001107-38 Sponsor Protocol Number: SESCHI.26371 Start Date*: 2008-05-26
    Sponsor Name:Cefak KG
    Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef...
    Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10019167 Hashimoto's thyroiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002576-18 Sponsor Protocol Number: A4061027 Start Date*: 2006-11-24
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT
    Medical condition: Treatment of patients with 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have cl...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055107 Thyroid cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-001684-21 Sponsor Protocol Number: NV1205-009 Start Date*: 2018-04-20
    Sponsor Name:Neurov Acquisition LLC
    Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-005063-34 Sponsor Protocol Number: CL1-11-040 Start Date*: 2009-09-14
    Sponsor Name:NPS Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyr...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021041 Hypoparathyroidism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) BE (Completed) GB (Completed) IT (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-006049-14 Sponsor Protocol Number: RG11_1128 Start Date*: 2012-05-18
    Sponsor Name:The University of Birmingham [...]
    1. The University of Birmingham
    2. Heart of England NHS Foundation Trust
    Full Title: Vildalgliptin and Glucose Variability in Type 2 Diabetes
    Medical condition: Diabetes and Cardiac risk benefit in South Asians.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001229-34 Sponsor Protocol Number: ALN-TTRSC-003 Start Date*: 2014-08-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis Who Have Previo...
    Medical condition: Transthyretin (TTR) Cardiac Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004528-36 Sponsor Protocol Number: CAC-002-01 Start Date*: 2011-10-06
    Sponsor Name:Asklepion Pharmaceuticals, LLC
    Full Title: An open-label, single center, non-randomized, continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis.
    Medical condition: Patients with inborn errors of bile acid synthesis and metabolism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10070882 Inborn error in primary bile acid synthesis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-003787-21 Sponsor Protocol Number: 201781-504 Start Date*: 2007-11-29
    Sponsor Name:Allergan Ltd
    Full Title: A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Treatment Period Followed by a 4-week Observation Period and an Optional 4 Month Observation Period of the Sa...
    Medical condition: Postherpetic neuralgia or post-traumatic peripheral neuralgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002278-24 Sponsor Protocol Number: BPLG-005-RO Start Date*: 2006-10-06
    Sponsor Name:BioPartners GmbH
    Full Title: A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: Growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) GB (Completed) FR (Ongoing) SE (Completed) SK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001427-40 Sponsor Protocol Number: ION-682884-CS13 Start Date*: 2022-06-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) CY (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004937-15 Sponsor Protocol Number: BNC210.006 Start Date*: 2015-04-16
    Sponsor Name:BIONOMICS LIMITED
    Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000998-23 Sponsor Protocol Number: CL1-64315-003 Start Date*: 2019-09-19
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in co...
    Medical condition: Locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004409-34 Sponsor Protocol Number: ESN364-PCO-201 Start Date*: 2015-01-21
    Sponsor Name:Ogeda S.A
    Full Title: Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Po...
    Medical condition: Polycystic Ovarian Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:23:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA